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Introduction {#sec1}
============

During embryonic development, gastrulation is marked by the formation of the primitive streak (PS). Within the PS, cells are directed to specific fates based on their spatiotemporal position. Thus, cells from the anterior part of the PS (APS) form the endoderm and cardiac mesoderm, whereas posterior PS (PPS) derivatives are destined to populate the extraembryonic and somitic mesoderm ([@bib23], [@bib28]). As a consequence, the anterior and posterior regions of the PS have unique differentiation potentials and depend on different transcription networks to guide their exit from pluripotency along the anterior-posterior PS axis.

The induction of the PS in mouse embryos or cultured human epiblast cells is directed by ACTIVIN/NODAL and WNT signaling ([@bib4], [@bib11], [@bib15], [@bib20], [@bib26]). In epiblast cells, WNT/β-CATENIN and ACTIVIN/SMAD2,3 cooperate to transcribe pan-PS lineage genes, such as *MIXL1* and *EOMES*. Relatively high levels of ACTIVIN direct APS differentiation toward endoderm (SOX17^*+*^), both *in vitro* and *in vivo*, while inhibiting posterior fates through the repression of PPS genes, such as *CDX2* ([@bib5], [@bib12], [@bib21]). In turn, posterior gene markers, such as *CDX2*, *MSGN1*, and *TBX6* are targets of WNT/β-CATENIN signaling. The expression of these latter genes correlates with WNT levels, and consequently stronger WNT signals contribute to the PPS fate ([@bib2], [@bib30], [@bib31]).

PS patterning also depends on other factors. For example, the DNA demethylase TET activates *Lefty* to downregulate NODAL levels along the streak in mouse embryos ([@bib6]), whereas the transcription factor ZFP281 represses *TET* expression to activate genes important for NODAL signaling, such as *Nodal* and *Foxh1* ([@bib9], [@bib13]). In addition, the tumor suppressor P53 regulates PS differentiation by repressing *Wnt3* expression in mouse embryonic stem cells (ESCs) ([@bib29]). Pluripotency factors are also key players of PS specification. For instance, early downregulation of SOX2 is required to exit pluripotency, whereas OCT4 regulates *SOX17* expression, and NANOG cooperates with SMAD2,3 to induce mid-anterior and APS fates via repression of *CDX2* ([@bib1], [@bib21], [@bib25]). These findings suggest that factors contributing to fine-tune WNT and NODAL signaling are key to pattern the PS.

Extending these findings, we recently discovered that the Hippo effector YAP1 ([@bib10]) strongly regulates the activity of WNT and ACTIVIN signaling in human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) ([@bib7], [@bib8]). Binding of the YAP1:TEAD complex to *WNT3* and *NODAL* enhancers in hESCs represses transcription of these ligands and block expression of WNT-ACTIVIN co-induced pan-PS genes. Importantly, long-term analysis of YAP1^−/−^ hESCs revealed that these cells differentiate selectively along the cardiac lineage in response to ACTIVIN. These findings suggest that YAP1 regulates genes important for differentiation toward the APS fate, which is the precursor of cardiac mesoderm.

To further elaborate the role of YAP1 in PS differentiation, we used both CRISPR-engineered YAP1 knockout hESCs and an inhibitor to temporally disrupt YAP1 activity in hESCs. We show that YAP1^−/−^ hESCs specify into APS progenitors (LHX1^+^/SOX17^+^/CDX2^−^/TBX6^−^) in response to ACTIVIN. The YAP^−/−^-derived APS cells further progress into cardiac mesoderm and endoderm. Importantly, we demonstrate that transient inactivation of YAP1 in hESCs using the dasatinib C-SRC/YAP1 inhibitor efficiently gave rise to functional cardiomyocytes using a one-step strategy. These findings demonstrate that YAP1 is a key regulator of APS specification, and provide a coherent strategy to guide stem cell differentiation along the endoderm and cardiac lineages.

Results {#sec2}
=======

Transient Inhibition of YAP1 Induces hESC Differentiation along the Anterior PS Cell Fate {#sec2.1}
-----------------------------------------------------------------------------------------

We have shown that YAP1^−/−^ hESCs progress toward cardiac lineage in response to ACTIVIN ([@bib8]). The cardiac lineage derives from the mid-anterior part of the PS, and therefore we hypothesize that inhibition of YAP1 activity in hESCs favors differentiation to anterior-like progenitors in response to ACTIVIN. Thus, we aimed to explore whether transient inactivation of YAP1 in hESCs affects the specification of PS progenitors ([Figure 1](#fig1){ref-type="fig"}A). To begin, we treated wild-type (WT) hESCs with dasatinib, a small-molecule C-SRC kinase inhibitor shown to affect the actin cytoskeleton and compromise the stability of YAP1 ([@bib32]). [Figure 1](#fig1){ref-type="fig"}B shows that 24 hr dasatinib (YAP1i) treatment in hESCs effectively decreased YAP1 protein levels along with a dose-dependent reduction of the YAP1 target gene, *CTGF*. We next tested whether transient exposure to YAP1i is sufficient to induce widely expressed pan-PS genes. As shown in [Figure 1](#fig1){ref-type="fig"}C, the combined ACTIVIN + YAP1i treatment in WT cells induced expression of *MIXL1*, *EOMES*, and *T* genes to levels comparable with those seen in YAP1^−/−^ hESCs treated with ACTIVIN. These results were consistent among two different hESCs lines (H1 and H9), also the EC11 iPSC line ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1YAP1 Depletion in hESCs Induces APS Fate in Response to ACTIVIN(A) A diagram illustrating the potential role of YAP1 in specifying PS fate.(B) Left: immunostaining of YAP1 and SOX2 in H1 hESCs treated with ACTIVIN or ACTIVIN + dasatinib (YAP1i) for 24 hr. Right: *CTGF* mRNA abundance (qRT-PCR) in H1 hESCs treated with dasatinib for 24 hr. The final concentration of dasatinib varied from 0, 5, and 10 to 20 nM.(C) mRNA abundance of tested pan-PS genes in WT and YAP1^−/−^ H1 hESCs at 24 hr following the indicated treatments.(D) An RNA-seq heatmap for two biological independent replicates of WT or YAP1^−/−^ H1 hESCs, untreated or treated with ACTIVIN for 24 hr.(E) mRNA abundance of APS (*LHX1* and *SOX17*) and PPS (*MSGN1* and *CDX2*) genes. The final concentration of dasatinib (YAP1i) was 10 nM. n ≥ 3 biological independent experiments, mean ± SD.Statistical significance of difference by paired two-tailed t test; ^∗^p \< 0.05; ^∗∗∗^p \< 0.001. Non-significant differences are not marked.

hESCs can differentiate into anterior- and posterior-like PS cells, which are partially committed precursors that give rise to distinct mesoderm and endoderm tissues. To further investigate the identity of the YAP1-depleted PS cells, we examined their transcriptome by RNA sequencing (RNA-seq) ([@bib8]). Surprisingly, we found that ACTIVIN-treated YAP1^−/−^ hESCs express high levels of APS markers, such as *SOX17*, *LHX1*, and *HAND1*, but low levels of PPS markers (*MSGN1*, *CDX2*, and *HOXA1*) compared with ACTIVIN-treated WT hESCs. Moreover, we found that hESCs treated with ACTIVIN + YAP1i also express high levels of APS, but not PPS markers ([Figure 1](#fig1){ref-type="fig"}E). We conclude that ACTIVIN treatment in YAP1-null human pluripotent stem cells (hPSCs) induces APS fate. Overall, these data show that YAP1 regulates the A-P specification of PS, and provides a specific approach to generate APS cells from hPSCs *in vitro*, through a brief exposure to ACTIVIN and dasatinib (YAP1i).

YAP1 Does Not Regulate Differentiation to Posterior PS Cell Fate {#sec2.2}
----------------------------------------------------------------

In hESCs, a strong WNT/β-CATENIN signal promotes the induction of PPS fate. In agreement with this finding, RNA-seq analysis of WNT signaling in WT hESCs treated with a GSK3 inhibitor (GSK3i) (factor XV), revealed strong expression of pan-PS and PPS genes, including *MSGN1*, *EVX1*, and *HOXA1*, but no significant induction of the APS transcriptome ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, loss of YAP1 did not significantly affect the induction of the PPS genes by GSK3i. Neither inhibition nor loss of YAP1 altered the induction of PPS genes in response to ACTIVIN ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}). In contrast, YAP1 inactivation potentiated the expression of some APS genes under GSK3i treatments, including *HHEX* and *LHX1* ([Figures 2](#fig2){ref-type="fig"}A--2C), but the effect was less dramatic relative to that seen in ACTIVIN-treated cells. Taken together, these results indicate that YAP1 selectively represses the APS genes in hESCs by counteracting ACTIVIN signaling.Figure 2Differentiation to PPS Fate Is Independent of YAP1(A) An RNA-seq heatmap of WT or YAP1^−/−^ H1 hESCs, untreated, or treated with either ACTIVIN or GSK3i for 24 hr, as indicated (two biological independent replicates).(B) Representative loci of APS and PPS genes from RNA-seq.(C) A bubble chart to summarize the dependency of pan-PS, APS, and PPS induction on YAP1 activity. Bubble sizes represent the log2 scale average gene expression. Bubble colors represent YAP1 logFC, defined as the average logFC of YAP1^−/−^ over WT expression under each treatment (GSKi or ACTIVIN).(D) mRNA abundance of *LHX1* and *MSGN1* in WT and YAP1^−/−^ H1 hESCs treated as indicated, for 24 hr. The final concentration of dasatinib (YAP1i) was 10 nM. n = 3 biological independent experiments, mean ± SD.^∗^p \< 0.05; ^∗∗∗^p \< 0.001.

ACTIVIN + Dasatinib (YAP1i)-Derived PS Cells Can Differentiate along the Endoderm and Cardiac Cell Lineages {#sec2.3}
-----------------------------------------------------------------------------------------------------------

These data show that exposure of hESCs to a combination of ACTIVIN with dasatinib (YAP1i) leads to strong induction of APS genes, whereas WNT/GSK3i induces the PPS genes. These divergent roles of ACTIVIN and WNT in specifying PS cell fates prompted us to assess possible differences in their developmental potential. We first evaluated the ability of the ACTIVIN + YAP1i-induced PS cells to differentiate toward two anterior derivatives, endoderm and the cardiac lineages. Following 24 hr incubation with ACTIVIN and YAP1i, the medium was replaced and the cells were analyzed following a total of 5 days in culture. As shown in [Figures 3](#fig3){ref-type="fig"}A and 3B, the ACTIVIN + YAP1i-induced PS cells expressed high levels of the cardiac precursor marker, *NKX2.5* ([@bib24]), indicating that these cells acquired a cardiac lineage without any additional treatment (condition C). To test whether the ACTIVIN + YAP1i-derived PS cells can differentiate into endoderm, the cells were exposed to a prolonged ACTIVIN signaling (days 2--5) ([@bib18]). Importantly, the ACTIVIN + YAP1i-exposed PS cells express high levels of *SOX17*, strongly suggesting that these precursors had differentiated to endoderm cells ([Figures 3](#fig3){ref-type="fig"}A and 3B, condition D).Figure 3ACTIVIN + Dasatinib (YAP1i)-Derived PS Cells Differentiate into Endoderm and Cardiac Lineages(A) The diagram illustrates the different procedures that were tested for hESC differentiation.(B) mRNA abundance of *MEOX1*, *NKX2.5*, and *SOX17* on day 5 from the initial treatments in H1 hESCs, as indicated in diagram. n = 3 biological independent experiments, mean ± SD. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001.(C) The diagram illustrates the various signaling cues that direct PS fate specification to mesendodermal lineages.

Finally, we examined the capacity of the ACTIVIN + YAP1i-treated cells to differentiate into posterior derivatives by analyzing the expression of the paraxial gene *MEOX1* ([@bib19]) at day 5 following the initial treatment. Interestingly, we found that *MEOX1* expression remained low in the ACTIVIN + YAP1i-treated cells ([Figure 3](#fig3){ref-type="fig"}B, condition C) in contrast to the high expression in the GSK3i-treated cells ([Figure 3](#fig3){ref-type="fig"}B, condition B). In accordance with their posterior nature, the GSK3i-induced PS cells failed to differentiate into anterior cardiac lineages or endoderm ([Figure 3](#fig3){ref-type="fig"}B, condition A). Overall, we conclude that unlike GSK3i, a treatment combining ACTIVIN and YAP1i is effective to generate PS precursors with a differentiation capacity toward anterior and mid-anterior derivatives.

PS Progenitors Can Be Reprogrammed {#sec2.4}
----------------------------------

We have demonstrated that GSK3i-induced PPS cells are prone to acquire a paraxial fate. Therefore, it seems contrary to employ WNT ligands or GSK3i as the most common practice for inducing cardiac differentiation. Noteworthy, the GSK3i-dependent cardiomyocyte differentiation requires an additional step at 3 days that is designed to block further WNT signaling (referred to as GiWi protocol in [@bib14], [@bib17]).

It is shown that the addition of a WNT inhibitor is necessary to cease the expression of key cardiac inhibitors such as *CDX2* and *MSX1*, allowing the cells to adopt a cardiac fate ([@bib25]) ([Figure S3](#mmc1){ref-type="supplementary-material"}). We hypothesize that the WNT inhibitor may also serve to suppress the expression of paraxial markers, and therefore redirect the posterior PS cells toward cardiac mesoderm. To test this possibility, we analyzed the expression of paraxial and cardiac genes in the presence or absence of WNT inhibitor, which was added 2 days following the GSK3i treatment ([Figure 3](#fig3){ref-type="fig"}A, conditions A and B). As predicted, [Figure 3](#fig3){ref-type="fig"}B (condition B) shows that the exposure to a WNT inhibitor strongly favors the induction of the cardiac lineage marker *NKX2.5* in GSK3i-treated cells. More importantly, the WNT inhibitor also impairs the induction of the paraxial gene, *MEOX1*. Consequently, blocking of WNT signaling reprograms the PPS precursors from a paraxial to a cardiac cell fate ([Figure 3](#fig3){ref-type="fig"}B, conditions A and B). These findings demonstrate that APS and PPS cells are not fully committed precursors, but rather can be redirected to alternate fates in response to appropriate developmental cues.

ACTIVIN + YAP1i Treatment Provides an Alternative Strategy for Cardiac Induction {#sec2.5}
--------------------------------------------------------------------------------

Thus far, these data strongly indicate that combined treatment of ACTIVIN and YAP1i during the first 24 hr of differentiation in WT hESCs and hiPSCs is sufficient to generate APS cells that efficiently differentiate into cardiac mesoderm (NKX2.5^+^/GATA4^+^/CDX2^−^) ([Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}). Thus, we reasoned that transient ACTIVIN + YAP1i exposure might provide an alternative strategy to generate cardiomyocytes in WT hESCs ([Figure 4](#fig4){ref-type="fig"}A). To test this possibility, we investigated the expression of cardiac markers following a full 14 days of differentiation. Indeed, ACTIVIN + YAP1i-treated hESCs express high levels of the CTNT, MLC2-A, and NKX2.5 cardiac markers ([Figure 4](#fig4){ref-type="fig"}B). Importantly, fluorescence-activated cell sorting analysis revealed that approximately 70% of the ACTIVIN + YAP1i-treated PS cells were CTNT positive, which is similar to the cardiomyocyte yield from the GiWi protocol ([@bib14]) ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B). In addition, active beating cardiomyocytes derived from ACTIVIN + YAP1i treatment were observed in culture from day 8 onward ([Video S1](#mmc4){ref-type="supplementary-material"}). As shown in the Venn diagram of [Figure 4](#fig4){ref-type="fig"}D, the transcriptome of the ACTIVIN + YAP1i-derived cardiomyocytes shows extensive overlap with that of cardiomyocytes derived using the GiWi protocol, and the heatmap further establishes that key cardiac marker genes are strongly expressed in cardiac cells derived from both protocols.Figure 4ACTIVIN + Dasatinib (YAP1i) Treatment Is an Alternative Strategy for Cardiomyocyte Differentiation(A) Steps of the GiWi and one-step protocols for cardiomyocyte differentiation.(B) Immunoblots of MLC-2A, CTNT, and NKX2.5 expression on day 14 of H1 hESC treatment.(C) Fluorescence-activated cell sorting analysis of CTNT^+^ cells on day 14 of treatments. n = 3 biological independent experiments, mean ± SD. ^∗∗∗^p \< 0.001.(D) Left: a Venn diagram summarized the RNA-seq data showing upregulated genes in cardiomyocytes derived from GiWi or one-step protocols. Right: a heatmap of the top 50 upregulated cardiac genes in H1 hESCs and cardiomyocytes generated from the GiWi or one-step protocols, respectively. Two biological independent experiments of hESCs and GiWi-derived cardiomyocytes (CMs), and three biological independent experiments of YAP1i-derived CMs.(E) Immunostaining of CTNT in cardiomyocytes derived from WT or YAP1^−/−^ H1 hESCs following the GiWi or one-step protocols.(F) The schematic depicts the strategy of APS specification for cardiac mesoderm and endoderm differentiation.

Video S1. Beating Cells on Day 14 of YAPi + ACTIVIN Treatment

We have recently reported that YAP1^−/−^-derived cardiomyocytes are viable; however, the organization of the actin cytoskeleton is significantly compromised ([@bib8]), as shown by immunostaining with CTNT ([Figure 4](#fig4){ref-type="fig"}E). Importantly, analysis of the ACTIVIN + YAP1i-derived cardiomyocytes revealed an intact actin cytoskeleton that resembles cardiomyocytes obtained using the GiWi strategy. We conclude that the one-step strategy (ACTIVIN + dasatinib \[YAP1i\]) is an effective approach for the generation of functional cardiomyocytes. In summary, this work shows that ACTIVIN + YAP1i co-treatment in hESCs provides a robust method to generate APS cells that effectively differentiate into endoderm and cardiac lineages ([Figure 4](#fig4){ref-type="fig"}F).

Discussion {#sec3}
==========

Transcription factors involved in primitive streak patterning play an essential role in early organogenesis and stem cell differentiation. Here, we show that YAP1 is a key regulator of PS cell specification through its ability to selectively repress the expression of genes for APS fate. We find that YAP1 represses ACTIVIN target genes, including *SOX17*, without affecting the expression of PPS genes. As a result, the loss of YAP1 in hESCs exposed to ACTIVIN enables efficient differentiation toward the APS cell fate. We previously showed that YAP1 inhibits hESC differentiation to cardiac mesoderm ([@bib8]). Here, we extend these findings by showing that YAP1 inhibits APS gene expression to restrain the cardiac fate. Moreover, we further discovered that APS cells generated from hESCs treated with ACTIVIN and the YAP1-inhibitor dasatinib can further differentiate to endoderm cells capable of further development to lung, liver, or pancreatic β cells.

How does YAP1 repress APS fate in hESCs? Several lines of evidence suggest that ACTIVIN acts in a dose-dependent manner to induce APS cell fate. In mouse models and ESCs, high ACTIVIN levels induce the APS markers *Sox17*, *Foxa2*, and *Cer1*, and repress the PPS marker *Cdx2* ([@bib4], [@bib8], [@bib21]). Our observation that YAP1 represses *NODAL* in hESCs raises the possibility that elevated SMAD2,3 signaling in YAP1^−/−^ cells may contribute to this phenotype ([@bib8]). Nevertheless, high ACTIVIN/NODAL signaling is not sufficient to induce an APS fate in WT hESCs, indicating the existence of other key YAP1 targets. Consistent with this idea, we find that YAP1 counteracts the ability of ACTIVIN/SMAD2,3 to repress the *WNT3* gene in hESCs. In the absence of YAP1, SMAD2,3 activate endogenous *WNT3* and nuclear β-CATENIN to initiate the PS program. Consequently, exposure of hESCs to WNT or GSK3i can overcome the ability of YAP1 to repress pan-PS genes in response to ACTIVIN. However, GSK3i treatment or WNT signaling does not bypass the need for YAP1 to repress the APS genes. Consequently, the APS gene program is induced in response to ACTIVIN only in cells that lack YAP1 activity. What are the key YAP1 targets? RNA-seq analysis of YAP1^−/−^ hESCs exposed to ACTIVIN revealed *SOX17*, a master regulator of endoderm and cardiac mesoderm specification ([@bib16], [@bib27]). In addition to pan-PS genes, we speculate that YAP1 also counteracts SMAD2,3-dependent transcription on APS genes, such as *SOX17*, to regulate PS specification. Further studies are needed to examine whether YAP1 and SMAD2,3 bind differentially to APS and PPS genes. Taken together, we conclude that YAP1 depletion in hESCs unlocks the ability of ACTIVIN to induce differentiation by activating endogenous WNT3 signaling and allowing SMAD2,3 to induce pan-PS and APS genes, such as *SOX17*.

hPSC differentiation is an excellent model to identify new regulators and mechanisms of cell differentiation in embryos ([@bib3]). Accordingly, the phenotype of YAP1^−/−^ embryos recapitulates the misregulation of the PS gene expression that we observe in YAP1^−/−^ hESCs. YAP1^−/−^ embryos die soon after the onset of gastrulation, indicating a crucial role of YAP1 in the specification of three germ layers *in vivo*. Analyses of embryos at the peri-gastrulation stage reveals that the PS in YAP1^−/−^ embryos appears shorter and broader than in WT embryos ([@bib22]). We speculate that the anterior-posterior axis defects in YAP1^−/−^ embryos reflect the inability of YAP1 to repress APS genes. These findings suggest that the PS abnormality in YAP1^−/−^ embryos might include an expanded APS domain (SOX17^+^/CDX2^−^) with a curtailed or absent PPS domain (CDX2^+^), similar to YAP1^−/−^ hESCs that preferentially induce the APS but not PPS program. In addition, YAP1 expression in developing embryos is lower within the region of the PS destined to become endoderm later in development. Thus, low levels of YAP1 likely favor the *in vivo* specification of APS precursors, as we observed in hESCs. Altogether, these findings suggest that distinct levels of YAP1 along the anterior-posterior axis could serve as a sensor to enable cells to exit pluripotency and adopt specific PS fates.

Lastly, we extend our findings to an alternative strategy for directing hESC and iPSC differentiation using a combined ACTIVIN and dasatinib (YAP1i) treatment. We show that a transient exposure of WT hESCs to ACTIVIN and dasatinib is sufficient to generate beating cardiomyocytes. Of note, we find that including ACTIVIN and dasatinib in the stem cell medium, without additional supplements, is sufficient to initiate hESC specification along the APS lineage. This simple procedure illuminates the critical control of ACTIVIN signaling and YAP1 activity in APS induction. Most importantly, the transient inhibition of YAP1 eliminates the severe cytoskeletal defects observed in YAP1^−/−^ hESC-derived cardiomyocytes, and bypasses the need for cell engineering. Consequently, the use of ACTIVIN and dasatinib to induce hESCs and iPSCs to undergo APS differentiation along the cardiomyocyte lineage may provide a useful step toward the therapeutic goals of regenerative medicine.

Experimental Procedures {#sec4}
=======================

ACTIVIN One-Step Cardiomyocyte Differentiation {#sec4.1}
----------------------------------------------

WT hESC cultures were disaggregated into single cells using Accutase. Cells were seeded at 200,000 cells/well in Matrigel-coated 24-well plates and grown until reaching 80% confluence. At day 0, hESCs were simultaneously treated with dasatinib (10 nM, Sigma) and ACTIVIN (100 ng/mL) in the mTeSR1 medium for 24 hr. Then, the medium was aspirated and replenished with RPMI/B-27 minus insulin and replaced every 2 days. From day 7, differentiated cells were maintained in RPMI/B-27 containing insulin and replenished in every 3 days. Spontaneous beating phenotype should occur from day 7 to 9 onward.

RNA-Seq Analysis {#sec4.2}
----------------

See [Supplemental Information](#app3){ref-type="sec"}.

Author Contributions {#sec5}
====================

H.-T.H. and C.E. conceived the study, designed and performed the experiments, and wrote the manuscript. L.H. performed the bioinformatics analysis of the sequencing data. K.A.J. designed the experiments and wrote the manuscript.

Accession Numbers {#app1}
=================

Analyzed data are provided in Supplemental Tables. Genome-wide datasets are deposited at the GEO under accession number GEO: [GSE121877](ncbi-geo:GSE121877){#intref0010a} and [GSE99202](ncbi-geo:GSE99202){#intref0010}.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S4, and Table S3Table S1. Table S1 Contains a List of Genes Grouped in Distinct Categories (Pan-PS, APS, and PPS) from the RNA-Seq Analysis of WT and YAP1^−/−^ hESCs after GSK3i or ACTIVIN Treatment, Related to Figures 1 and 2Table S2. RNA-Seq of Cardiomyocytes Obtained by GiWi and One-Step Protocols, Related to Figure 4Document S2. Article plus Supplemental Information

We acknowledge support from Salk Bioinformatics and Stem Cell Cores. This work is funded by the California Institute for Regenerative Medicine (GC1R-06673-B) and NIH/NCI RO1CA125535 (to K.A.J.). Conchi Estarás was supported by Salkexcellerators Program.

Supplemental Information includes Supplemental Experimental Procedures, four figures, three tables, and one video and can be found with this article online at [https://doi.org/10.1016/j.stemcr.2018.10.013](10.1016/j.stemcr.2018.10.013){#intref0015}.

[^1]: Co-first author
